Carra-Dallière C - Search Results

1

TWEAK and TNFɑ Pro-inflammatory Soluble Cytokines and their Specific Autoantibodies Secretion in Multiple Sclerosis Patients.

Carmona S, Aghzadi J, Vincent T, Labauge P, Carra-Dallière C, Lehmann S, Desplat-Jégo S, Ayrignac X. Carmona S, et al. Among authors: carra dalliere c. Inflammation. 2024 Dec 6. doi: 10.1007/s10753-024-02205-0. Online ahead of print. Inflammation. 2024. PMID: 39641859

2

Atypical inflammatory demyelinating lesions and atypical multiple sclerosis.

Ayrignac X, Carra-Dallière C, Labauge P. Ayrignac X, et al. Rev Neurol (Paris). 2018 Jun;174(6):408-418. doi: 10.1016/j.neurol.2018.03.007. Epub 2018 Apr 16. Rev Neurol (Paris). 2018. PMID: 29673573 Review.

3

Diagnostic and therapeutic issues of inflammatory diseases of the elderly.

Ayrignac X, Carra-Dallière C, Labauge P. Ayrignac X, et al. Rev Neurol (Paris). 2020 Nov;176(9):739-749. doi: 10.1016/j.neurol.2020.03.014. Epub 2020 Apr 17. Rev Neurol (Paris). 2020. PMID: 32312496 Review.

4

Serum GFAP in multiple sclerosis: correlation with disease type and MRI markers of disease severity.

Ayrignac X, Le Bars E, Duflos C, Hirtz C, Maleska Maceski A, Carra-Dallière C, Charif M, Pinna F, Prin P, Menjot de Champfleur N, Deverdun J, Kober T, Marechal B, Fartaria MJ, Corredor Jerez R, Labauge P, Lehmann S. Ayrignac X, et al. Sci Rep. 2020 Jul 2;10(1):10923. doi: 10.1038/s41598-020-67934-2. Sci Rep. 2020. PMID: 32616916 Free PMC article.

5

CSF β-amyloid is not a prognostic marker in multiple sclerosis patients.

Petitfour J, Ayrignac X, Ginestet N, Prin P, Carra-Dallière C, Hirtz C, Charif M, Lehmann S, Labauge P. Petitfour J, et al. Mult Scler Relat Disord. 2022 Dec;68:104096. doi: 10.1016/j.msard.2022.104096. Epub 2022 Aug 8. Mult Scler Relat Disord. 2022. PMID: 36037751

6

Serum NfL and GFAP are weak predictors of long-term multiple sclerosis prognosis: A 6-year follow-up.

Ayrignac X, Aouinti S, Vincent T, Carra-Dallière C, Charif M, Duflos C, Hirtz C, Dos Santos A, Menjot de Champfleur N, Labauge P, Lehmann S. Ayrignac X, et al. Among authors: carra dalliere c. Mult Scler Relat Disord. 2024 Sep;89:105747. doi: 10.1016/j.msard.2024.105747. Epub 2024 Jun 24. Mult Scler Relat Disord. 2024. PMID: 39053395

7

Lack of confirmation of anti-inward rectifying potassium channel 4.1 antibodies as reliable markers of multiple sclerosis.

Nerrant E, Salsac C, Charif M, Ayrignac X, Carra-Dalliere C, Castelnovo G, Goulabchand R, Tisseyre J, Raoul C, Eliaou JF, Labauge P, Vincent T. Nerrant E, et al. Mult Scler. 2014 Nov;20(13):1699-703. doi: 10.1177/1352458514531086. Epub 2014 Apr 22. Mult Scler. 2014. PMID: 24756568

8

Late activity rebound in non-active multiple sclerosis: A rare event.

Corti L, Ayrignac X, Carra Dalliere C, Charif M, de Sèze J, Biotti D, Ciron J, Labauge P. Corti L, et al. Mult Scler. 2018 Oct;24(12):1649-1650. doi: 10.1177/1352458518765670. Epub 2018 Mar 13. Mult Scler. 2018. PMID: 29533160 No abstract available.

9

Posterior fossa involvement in the diagnosis of adult-onset inherited leukoencephalopathies.

Ayrignac X, Boutiere C, Carra-Dalliere C, Labauge P. Ayrignac X, et al. J Neurol. 2016 Dec;263(12):2361-2368. doi: 10.1007/s00415-016-8131-2. Epub 2016 Apr 28. J Neurol. 2016. PMID: 27126452 Review.

10

From Baló's concentric sclerosis to multiple sclerosis: a series of 6 patients.

Ayrignac X, Letourneau-Guillon L, Carra-Dallière C, Duquette P, Girard M, Poirier J, Lahav B, Larochelle C, Prat A. Ayrignac X, et al. Mult Scler Relat Disord. 2020 Jul;42:102078. doi: 10.1016/j.msard.2020.102078. Epub 2020 May 4. Mult Scler Relat Disord. 2020. PMID: 32408148

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

82 results

Search Page

Filters